Agoracom Blog Home

Archive for the ‘Medical Marijuana Stocks’ Category

« Older Entries
Newer Entries »

MCOA Finalizes Joint Venture Agreement With Bougainville Ventures in Washington State $MCOA.us

Posted by AGORACOM-JC at 1:16 PM on Tuesday, April 4th, 2017

15233 mcoa

  • Finalized the joint venture agreement with Bougainville Ventures, Inc. in Washington State
  • MCOA will invest $1 million in cash in a newly formed entity
  • Bougainville Ventures, Inc. will contribute its expertise in the construction and management of a 30,000 sq. ft. greenhouse facility

BONSALL, CA–(Apr 4, 2017) – MARIJUANA COMPANY OF AMERICA (“MCOA” or the “Company”) (OTC PINK: MCOA), an innovative cannabis and hemp marketing and distribution Company, is pleased to announce that it has finalized the joint venture agreement with Bougainville Ventures, Inc. (“BV”) in Washington State.

MCOA will invest $1 million in cash in a newly formed entity. Bougainville Ventures, Inc. will contribute its expertise in the construction and management of a 30,000 sq. ft. greenhouse facility, which will accommodate a Tier-3 production and processing I-502 tenant that has decades of experience and a proven track record of consistency and quality. MCOA and BV will split equity and profits equally, 50/50.

As turnkey landlords, MCOA and BV will provide our I-502 tenant with a state-of-the-art facility that creates an ideal cultivation environment that they can move into and be fully operational on day one. This enables our tenants to focus on what they do best, producing top quality products and not worrying about maintaining their infrastructure.

Donald Steinberg, MCOA President and CEO, said, “This project will help to expand our operations as an ancillary business into the Washington State market. Achieving this milestone of closing this deal, as well as completing our PCAOB audit at the end of the first quarter are two more pillars of the strong foundation we are building for our shareholders.”

The execution of the agreement is the final step in formalizing the Letter of Intent that was publicly announced on February 15, 2017. This joint venture partnership is formed for the purpose of greenhouse construction, management and commercial leasing to I-502 licensed producers within Washington State only and not beyond its borders.

ABOUT BOUGAINILLE VENTURES, INC.

Bougainville Venture Inc. is in the core business of converting irrigated farmland that was traditionally used to grow marginally profitable feed crops, to greenhouse-equipped farmland used to grow luxury crops with a primary focus on high-density and high-yielding crops. Bougainville is an agricultural services company that focuses on providing growers with state-of-the-art computer controlled greenhouses and processing facilities. Bougainville offers fully built out turnkey solutions to tenant-growers and provides growing infrastructure, as well as landlord services for licensed I-502 producers and processors in the state of Washington.

SAFE HARBOR STATEMENT

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For more information, please visit the Company’s websites at:
MarijuanaCompanyofAmerica.com
hempSMART.com
agoracom.com/ir/MarijuanaCompanyofAmerica

Marijuana Company of America
Investor Relations
1+(888)-777-4362
[email protected]

Tags: , , , ,
Posted in Marijuana Company of America, Medical Marijuana Stocks | Comments Off on MCOA Finalizes Joint Venture Agreement With Bougainville Ventures in Washington State $MCOA.us

Tetra Bio-Pharma and IntelGenx Announce the Signing of a Definitive Agreement for the Development and Commercialization of a Dronabinol XL Tablet $TBP.ca

Posted by AGORACOM-JC at 8:45 AM on Monday, April 3rd, 2017

Tbp large

  • Signed definitive agreement for the development and commercialization of a drug product containing the cannabinoid Dronabinol
  • for the management of anorexia and cancer chemotherapy-related pain
  • U.S. cancer pain market is expected to reach $5 billion in 2018

OTTAWA, ONTARIO–(April 3, 2017) – Tetra Bio-Pharma Inc. (“Tetra“) (CSE:TBP)(OTC PINK:GRPOF) and IntelGenx Corp. (“IntelGenx”) (TSX VENTURE:IGX)(OTCQX:IGXT), today announced the signing of a definitive agreement for the development and commercialization of a drug product containing the cannabinoid Dronabinol (the “Product”) for the management of anorexia and cancer chemotherapy-related pain. The U.S. cancer pain market is expected to reach $5 billion in 2018. This definitive agreement follows the binding term sheet between the two companies that was announced on February 9, 2017.

Pursuant to the definitive agreement, Tetra has exclusive rights to sell the Product in North America, with a right of first negotiation for territories outside of the United States and Canada. Tetra will make an upfront payment to IntelGenx, in addition to set future milestone and royalty payments, based on the completion of an efficacy study, approvals from the U.S. Food and Drug Association (“FDA”) and Health Canada, and the commercial launch of the Product. IntelGenx will be responsible for the research and development of the Product, including clinical studies, and will develop the product as an oral mucoadhesive tablet based on its proprietary AdVersa® controlled-release technology. Tetra will be responsible for funding the product development, and will own and control all regulatory approvals, including the related applications, and any other marketing authorizations. Tetra will also be responsible for all aspects of commercializing the Product.

“We are pleased to announce the closing of the definitive agreement with IntelGenx and look forward to working very hard with them to bring this much-needed product to patients suffering from cancer pain,” said Andre Rancourt, CEO of Tetra Bio-Pharma Inc. “The execution of this agreement is just the beginning for Tetra as we look forward to aggressively concluding future agreements as we build a leading bio-pharmaceutical organization focused on developing medicinal cannabis as pharmaceutical drugs.”

“The U.S. cancer pain market is expected to reach $5 billion in 2018, and the quick growing medical cannabis industry is poised to capture a signature portion of that opportunity,” said Dr. Horst G. Zerbe, President and CEO of IntelGenx. “We are pleased to be working with Tetra to bring this much-needed cannabinoid product to North American patients suffering from anorexia and cancer chemotherapy-related pain.”

Background Information: 

There are many clinical problems associated with the use of currently available form of Dronabinol in patients with anorexia and cancer chemotherapy-related pain. It has been demonstrated that psychoactive drugs exert their euphoria, and other psychoactive effects, when the blood levels of the drug rapidly increase. The pharmacokinetic profile of tetrahydrocannabinol (“THC”) and its metabolite increases the abuse potential of cannabinoids like Dronabinol. The significant advantage of an oral mucoadhesive tablet based on IntelGenx’ proprietary AdVersa® controlled-release technology is that it can be adjusted to achieve a predetermined drug release pattern by increasing the residence time, promoting intimate contact with the mucosal tissue and increasing the bioadhesive properties of the dosage form. It is believed that, by deploying this technology in the controlled-release of THC, a longer time release of the drug will be achieved and, thereby, a rapid increase in the blood will be avoided. There will also potentially be improved bioavailability and reduced gastro-intestinal side effects, making a sustained-release THC product a promising alternative in the battle for the reduction of opioids in patients with chronic pain.

About IntelGenx:

IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform. Established in 2003, the Montreal-based company is listed on the TSX-V and OTC-QX.

IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx state-of-the art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to our clients. More information is available about the company at: www.intelgenx.com.

About Tetra Bio Pharma: 

Tetra Bio Pharma is a multi subsidiary publicly traded company (CSE:TBP) (OTC PINK:GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
[email protected]
(343) 689-0714
www.tetrabiopharma.com

Tags: , ,
Posted in Featured, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma and IntelGenx Announce the Signing of a Definitive Agreement for the Development and Commercialization of a Dronabinol XL Tablet $TBP.ca

Marijuana industry gets boost from anticipated legalization target date $TBP.ca $MCOA.us

Posted by AGORACOM-JC at 9:55 AM on Tuesday, March 28th, 2017

Canadian marijuana businesses got a confidence boost from a CBC News report that the government plans to legalize recreational marijuana by July 2018, although big questions remain about how the legal market will work in different provinces.

The newly revealed date for the debut of legal cannabis is “exactly along the lines of what we expected,” said Neil Maruoka, a stock analyst with Canaccord Genuity who covers publicly traded marijuana companies.

“Certainly there are some companies with more aggressive expansion plans, and this will give some comfort and clarity on what that path forward is going to be,” he said.

Stocks in Canadian marijuana companies swelled on Monday. Shares of Canopy Growth Corp., Canada’s largest publicly traded marijuana producer, gained more than 11 per cent. Shares of Aphria, another large player, gained about 8.4 per cent.

The tabling of the legislation, expected the week of April 10, should be “the tide that lifts all cannabis stocks,” said Maruoka.

Licensed producers bet on recreational sales

Currently, 39 marijuana producers are licensed by Health Canada to cultivate medical marijuana and sell it to patients via a mail-order system. Some of those companies are spending heavily to build up their growing capacity, betting that they’ll be well positioned to sell into the recreational market as soon as the green flag waves.

Alberta-based Aurora Cannabis, which is building an 800,000 square-foot farm near Edmonton International Airport, welcomed the reassurance that Ottawa is committed to recreational sales.

“This is something that we planned on and that’s why we started construction on this enormous facility,” Aurora executive vice-president Cam Battley told CBC Edmonton on Monday.

Canopy Growth CEO Bruce Linton also said the legalization date is in line with his company’s plans.

“It means everything that’s been predicted to be on a path is on a path,” said Linton.

“And when you’re dealing with a government, you can expect things not to stay that course, but they have.”

Who will be allowed to sell?

Even if they weren’t surprised by the date, players in the Canadian marijuana market are taking notice of the news that individual provinces will be deciding how marijuana is sold.

“The dispensary groups, depending on how this plays out, could be big winners,” said Mark Lustig, CEO of CannaRoyalty Corp., which invests in legal aspects of the marijuana industry.

Pharmacies like Shoppers Drug Mart, London Drugs, and Jean Coutu could also benefit if provincial governments tap them as marijuana distributors, said Lustig.

CANADA MARIJUANA/REGULATIONS

Marijuana dispensaries, currently illegal under federal law, could benefit if individual provinces let them sell legal marijuana. (Julie Gordon/Reuters)

In Ontario, the union that represents Liquor Control Board of Ontario workers has pushed for marijuana sales through the government liquor monopoly.

Ontario Premier Kathleen Wynne said Monday that the provincial government has not yet decided who will get to sell marijuana in Canada’s most populous province, although she previously said “it makes sense” to sell marijuana through the LCBO.

Colette Rivet of the Cannabis Canada Association, which represents 15 licensed producers, says her organization’s members favour leaving the mail-order system for medical marijuana in place, and potentially expanding it to recreational sales.

Still, Rivet acknowledges that brick-and-mortar retail sales are “likely to happen, of course.”

In its submission to the federal task force on marijuana legalization, Cannabis Canada said it was against selling alcohol and marijuana in the same location.

Dispensaries hope for inclusion

Owners of some marijuana dispensaries, which are illegal under federal law, are also hoping the provinces will cut them in on the legal marijuana market.

“We feel that we have a very good potential to be included in a regulated environment,” said Jeremy Jacob, a Vancouver dispensary owner and president of the Canadian Association of Medical Cannabis Dispensaries.

In many Canadian cities, dispensaries are frequently raided and shut down by police. But Jacob points out that some B.C. dispensaries have good relationships with local governments in Vancouver and Victoria, where marijuana shops can be licensed by municipal authorities.

Jacob expressed hope that those existing government ties could help pave the way for dispensaries — and the unlicensed producers who grow their product — to take part in the legal marijuana economy in B.C.

“We’re waiting to see how inclusive they actually are,” said Jacob.

Source: http://www.cbc.ca/news/business/marijuana-businesses-legalization-date-1.4042599

Tags: , , , , ,
Posted in All Recent Posts, Marijuana Company of America, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Marijuana industry gets boost from anticipated legalization target date $TBP.ca $MCOA.us

Marijuana Company of America Completes 2-Year Audit, Will Apply to Uplist $MCOA.us

Posted by AGORACOM-JC at 8:56 AM on Tuesday, March 28th, 2017

15233 mcoa

  • Announced that its PCAOB auditors have completed a two year audit of the Company’s financial statements for the years ended December 31, 2015 and 2016
  • Company will apply to uplist its trading tier with OTC Markets to the OTCQB exchange

BONSALL, CA–(Mar 28, 2017) – MARIJUANA COMPANY OF AMERICA (“MCOA” or the “Company”) (OTC PINK: MCOA), an innovative cannabis and hemp marketing and distribution Company, is pleased to announce that its PCAOB auditors have completed a two year audit of the Company’s financial statements for the years ended December 31, 2015 and 2016.

MCOA‘s SEC legal counsel is now finalizing a Form 10 registration statement for filing with the Securities and Exchange Commission. After the registration statement becomes effective, and the Company’s common stock is registered with the Commission, the Company will apply to uplist its trading tier with OTC Markets to the OTCQB exchange. Completing the two year audit is an integral step in successfully filing a Form 10 registration statement. This significant step has been completed to enhance long-term shareholder value, and attract a broader and more diverse shareholder base, including more institutional investors.

Donald Steinberg, MCOA President and CEO said, “Our goal is to meet the requirements to be a fully reporting company. This is in-line with our business plan to move to a higher level stock exchange. As we continue to grow within our industry, achieving the highest level of transparency for our current and future shareholders is of paramount importance to us. With the audit completed, we are well on our way to becoming fully reporting and offering more transparency to investors and shareholders.”

ABOUT L&L CPAs, PA
L&L CPAs, PA is registered with the Public Company Accounting Oversight Board (PCAOB) and is experienced in conducting audits of public companies in the cannabis industry. Please visit the audit firm’s website at www.llcpas.net to find out more information about the firm.

SAFE HARBOR STATEMENT
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For more information, please visit the Company’s websites at:
MarijuanaCompanyofAmerica.com
hempSMART.com
Harmoneous.com
agoracom.com/ir/MarijuanaCompanyofAmerica

Contact :
Investor Relations
1+(888)-777-4362
[email protected]

Tags: , , , , ,
Posted in All Recent Posts, Marijuana Company of America, Medical Marijuana Stocks | Comments Off on Marijuana Company of America Completes 2-Year Audit, Will Apply to Uplist $MCOA.us

Marijuana could be legal by July 2018: report $TBP.ca $MCOA.us

Posted by AGORACOM-JC at 10:32 AM on Monday, March 27th, 2017

Cured flowers of cannabis intended for the medical marijuana market are seen at a licensed producer facility in Moncton, N.B., on April 14, 2016. THE CANADIAN PRESS/Ron Ward
  • federal Liberals have reportedly set a date to officially legalize marijuana
  • government will unveil legislation the week of April 10 and that the recreational use of marijuana is set to be legal by Canada Day of next year.
The federal Liberals have reportedly set a date to officially legalize marijuana.

The CBC reports the government will unveil legislation the week of April 10 and that the recreational use of marijuana is set to be legal by Canada Day of next year.

According to the Globe and Mail, the federal government is scrambling to draft legislation ahead of April 20, the day when pro-weed groups publicly “light up.”

The minimum age to buy pot will be 18, but provinces could set a higher limit. It’s also up to the provinces to control distribution and sales. Also, four marijuana plants will be allowed in each household.

Last year, Prime Minister Justin Trudeau had signalled the legislation would be drawn up this spring to make good on his campaign promise to legalize pot.

All storefront marijuana dispensaries are currently illegal while the federal government drafts legislation to legalize and regulate recreational pot.

Dispensaries have been frequent robbery targets over the last few months. Several shops have been held up, often at gunpoint, and in some instances shots were fired.

Earlier this month, police arrested Marc and Jody Emery – the owners of the Cannabis Culture brand – and raided a number of Cannabis Culture dispensaries across Canada.

Source: http://www.citynews.ca/2017/03/27/marijuana-legal-canada-day-2018-report/

Tags: , ,
Posted in All Recent Posts, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Marijuana could be legal by July 2018: report $TBP.ca $MCOA.us

Tetra Bio-Pharma Appoints Edward Miller as Vice President, Investor Relations & Corporate Communications $TBP.ca

Posted by AGORACOM-JC at 9:01 AM on Monday, March 27th, 2017

Tbp large

  • Announced that it entered into an employment agreement with Edward Miller as Vice President, Investor Relations and Corporate Communications effective today

OTTAWA, ONTARIO–(March 27, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF), today announced that it entered into an employment agreement with Edward Miller as Vice President, Investor Relations and Corporate Communications effective today.

Mr. Miller has over a decade of experience in the Biotech/Pharma industry. Most recently, he served as Director, Investor Relations and Corporate Communications at IntelGenx Corp. where he successfully built their shareholder communications program, resulting in substantial growth in their website traffic and social media hits. Mr. Miller joined Paladin Labs in 2001 where he held various positions including Manager, Investor Relations where he successfully built their investor relations program. Following his tenure at Paladin Labs he moved into the role as an investor relations consultant working for Christensen IR, heading their life science practice and as an independent where he has built award winning investor relations programs. Mr. Miller is the Past President of CIRI (Canadian Investor Relations Institute) Quebec Chapter where he served two terms (2009 – 2012) and (2005 – 2007). Mr. Miller will be contributing to improving the company’s visibility in the capital markets and leveraging his international experience at broadening its shareholder base.

“We are most pleased to welcome Edward to the team as we are focused on building Tetra as a leading bio-pharmaceutical organization,” said Andre Rancourt, CEO of Tetra Bio-Pharma. “Mr. Miller has built award winning investor relations programs that have driven shareholder value and visibility for several organizations in the market place. We look forward to expanding our communications outreach as we build an even stronger shareholder base moving forwards.”

About Tetra Bio-Pharma:

Tetra Bio Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Guy Chamberland
Chief Science Officer
(514) 220-9225

Tetra Bio-Pharma Inc.
Andre Rancourt
Chief Executive Officer
(343) 689-0714
www.tetrabiopharma.com

Tags: , ,
Posted in Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma Appoints Edward Miller as Vice President, Investor Relations & Corporate Communications $TBP.ca

MCOA Continues National Expansion with Production Permit in Adelanto, California $MCOA.us

Posted by AGORACOM-JC at 8:57 AM on Wednesday, March 22nd, 2017

15233 mcoa

  • Completed due diligence and entered into a binding joint venture agreement with GateC Research, Inc.
  • MCOA will invest cash and stock in a newly formed entity, and receive a 50% equity and share in the net profits produced in the joint venture in Adelanto, California, where GCR owns a permit for cultivation

BONSALL, CA–(Mar 22, 2017) – MARIJUANA COMPANY OF AMERICA (“MCOA” or the “Company”) (OTC PINK: MCOA), an innovative cannabis and hemp marketing and distribution company, is pleased to announce that it has completed due diligence and entered into a binding joint venture agreement with GateC Research, Inc. (“GCR”) for the purpose of engaging in the cultivation of legal marijuana in Adelanto, California.

The terms of the agreement include that MCOA will invest cash and stock in a newly formed entity, and receive a 50% equity and share in the net profits produced in the joint venture in Adelanto, California, where GCR owns a permit for cultivation.

A three-person board of managing members will oversee operations of the newly formed entity. GCR will contribute its expertise in marijuana cultivation, as well as establish partnerships and licensing agreements that will enable the legal cultivation of marijuana in the State of California.

Donald Steinberg, MCOA President and CEO, commented, “We are excited to work with the GateC Research, Inc. team, and we look forward to strengthening our supply chain pipeline in California. We have some very exciting marketing ideas to implement as regulations allow.”

“Our partners have managed many successful and legally compliant cultivation projects in California and we are looking forward to expanding our operations with MCOA’s assistance into Adelanto County and starting a cultivation model that we intend to successfully replicate with MCOA,” said Adam Agathakis, an Officer of GateC Research, Inc.

This joint venture project is solely for the purpose of cultivation, processing and distribution of legal marijuana within the State of California only and not beyond its borders.

GATEC RESEARCH, INC.

GateC Research, Inc. is a California based Mutual Benefit Corporation that has secured a permit to grow medical marijuana in Adelanto County. The Company’s principals are successful pioneers in the California and Washington state medical marijuana industry that have successfully owned and operated numerous successful pre-ico dispensaries and cultivation facilities. Eddie Manolos is an advisor of GateC Research and has been on MCOA’s advisory board since early in 2016.

SAFE HARBOR STATEMENT

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For more information, please visit the Company’s websites at:
MarijuanaCompanyofAmerica.com
hempSMART.com
Harmoneous.com
agoracom.com/ir/MarijuanaCompanyofAmerica

Marijuana Company of America, Inc.
Investor Relations
888-777-4362
[email protected]

Tags: ,
Posted in All Recent Posts, Marijuana Company of America, Medical Marijuana Stocks | Comments Off on MCOA Continues National Expansion with Production Permit in Adelanto, California $MCOA.us

Namaste Enters Into Non-Binding LOI With CannMart, a Late Stage ACMPR Applicant $N.ca

Posted by AGORACOM-JC at 9:51 AM on Tuesday, March 21st, 2017

Nlogo

  • Entered into a non-binding letter of intent with Cannmart Inc.
  • Namaste will purchase all of the issued and outstanding shares in the capital of CannMart, a late stage applicant under the Access to Cannabis for Medical Purposes Regulations
  • CannMart submitted its application to become a “sales only” licensed producer of medical cannabis

VANCOUVER, BRITISH COLUMBIA–(March 21, 2017) –

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES 

Namaste Technologies Inc. (“Namaste” or the “Company“) (CSE:N)(CSE:N.CN)(FRANKFURT:M5BQ)(OTCQB:NXTTF) is pleased to announce that it has entered into a non-binding letter of intent (the “LOI“) with Cannmart Inc. (“CannMart“) whereby Namaste will purchase all of the issued and outstanding shares in the capital of CannMart, a late stage applicant under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR“) (the “Contemplated Transaction“). In 2014, CannMart submitted its application to become a “sales only” licensed producer of medical cannabis (the “ACMPR Application“).

The Contemplated Transaction represents a significant strategic maneuver by Namaste in advance of the potential legalization and regulation of cannabis in Canada. The strategic rationale for the Contemplated Transaction includes:

  • Represents a logical expansion of the product portfolio and generates additional recurring revenue streams from existing and new customers throughout Canada. Creates a one-stop shopping platform for Canadian cannabis consumers;
  • Aligns with Namaste’s e-commerce capabilities and dataset of over 50,000 individuals in Canada, which represents a significant competitive advantage in terms of becoming one of the leading online retailers of cannabis;
  • Complements Namaste’s distribution expertise and relationships with the location of CannMart’s proposed facility enabling same day delivery in the Greater Toronto Area and 24-hour delivery within Canada. Namaste will seek to be the leading online retailer of cannabis in terms of fulfillment and customer service; and
  • Enhances the overall financial profile of the Company in terms of additional revenue and margin generation potential. Attractive non-cash purchase price based on comparable public companies within the industry.

CannMart’s ACMPR Application

CannMart’s ACMPR Application and proposed business model are unique in the industry as CannMart has applied only to sell and not produce medical cannabis. Under this model and subject to obtaining a licence from Health Canada, CannMart would have the ability to purchase wholesale medical cannabis from other licensed producers and sell to individual patients in accordance with the ACMPR.

The ACMPR Application has completed the “security clearance” stage and is currently in the “review” stage of the licensing process. CannMart’s proposed facility is a 4,000 sq. ft. industrial building located in Etobicoke, Ontario (the “Facility“). Pursuant to the LOI, the Company will assume all of the going forward liabilities and obligations of CannMart, including the remaining build-out costs needed to prepare the Facility for the final stages of the licensing process and the pre-licensing inspection.

Terms of the Contemplated Transaction

Upon execution of the LOI, Namaste paid $50,000 (the “Initial Payment“) in cash to CannMart’s counsel, to be held in trust and released upon closing of the Contemplated Transaction. If Namaste does not provide CannMart with notice of completion of its due diligence within 30 days of the execution of the LOI, the Initial Payment will become non-refundable. The parties anticipate signing a definitive agreement in mid-late April.

Consideration for the Contemplated Transaction will be satisfied with common shares in the capital of the Company. A portion of common shares of the Company will be issued on closing of the Contemplated Transaction, and the remaining common shares of the Company will be issued upon the occurrence of certain milestones. The share price shall be the five-day trailing volume weighted average price prior to the day on which the Company announces the Contemplated Transaction, subject to compliance with all stock exchange and regulatory requirements.

Clarus Securities Inc. is acting as financial advisor to Namaste in connection with the Contemplated Transaction.

Conditions to Closing

Closing of the Contemplated Transaction is subject to the following:

  • Completion of a definitive share purchase agreement containing representations, warranties and covenants customary in a transaction of this nature;
  • Completion of all financial and legal due diligence;
  • Execution of an employment or consulting agreement with each of CannMart’s existing team members for the purposes of the MMPR Application or longer;
  • Receipt of all director and shareholder approvals, if necessary, and requisite regulatory approvals of each party relating to the Contemplated Transaction;
  • Each of the current directors and officers of CannMart (other than as agreed to by Namaste) having delivered resignations and releases to CannMart; and
  • Such other documentation and closing conditions as are customary for transactions similar to the Contemplated Transaction.

Management Commentary

Mr. Sean Dollinger, President and CEO of Namaste, comments: “The acquisition of CannMart represents a significant strategic transaction for Namaste. One of the core competitive advantages of Namaste is the international customer list we have built, which enables us to enter markets with new product offerings and instantly generate revenues. The addition of consumables to our product offering in Canada is an excellent example of this competitive advantage and we see multiple opportunities to obtain additional licences in international jurisdictions where we have a strong customer foothold.”

About Namaste Technologies Inc.

Namaste Technologies Inc. is an emerging leader in vaporizer and accessories space. Namaste has 26 ecommerce retail stores in 20 countries, offers the largest range of brand name vaporizers products on the market and is actively manufacturing and launching multiple unique proprietary products for retail and wholesale distribution. The Company is currently focused on expanding its product offering, acquisitions and strategic partnerships, and entering new markets globally.

On behalf of the Board of Directors

Sean Dollinger

Chief Executive Officer

Further information on the Company and its products can be accessed through the links below:

www.namastetechnologies.com

www.namastevaporizers.com

www.namastevaporizers.co.uk

www.vaporseller.com

www.everyonedoesit.com

www.everyonedoesit.co.uk

FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

Namaste Technologies Inc.
Sean Dollinger
Chief Executive Officer
+1 (786) 389 9771
[email protected]

Tags: , , , , ,
Posted in Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Namaste Enters Into Non-Binding LOI With CannMart, a Late Stage ACMPR Applicant $N.ca

Aphria Exercises Warrants for Gross Proceeds of $1.3 Million to Further Fund Tetra’s Clinical Trials $TBP.ca

Posted by AGORACOM-JC at 9:31 AM on Monday, March 20th, 2017

http://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564502/hub/TBP_large.jpg

  • Aphria Inc. (TSX VENTURE:APH)(OTCQB:APHQF) has exercised their 5,000,000 warrants for aggregate gross proceeds of $1,300,000
  • Proceeds from the warrant exercise will be used to advance the clinical trials being developed in PhytoPain Pharma Inc., a subsidiary of Tetra

OTTAWA, ONTARIO–(March 20, 2017) – Tetra Bio-Pharma Inc. (“Tetra Bio” or “the Company”) (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF) is pleased to announce that Aphria Inc. (TSX VENTURE:APH)(OTCQB:APHQF) has exercised their 5,000,000 warrants for aggregate gross proceeds of $1,300,000. The proceeds from the warrant exercise will be used to advance the clinical trials being developed in PhytoPain Pharma Inc., a subsidiary of Tetra.

“We would like to thank Aphria for their continued support and investment in the research and development being conducted by the science team at Tetra,” said Andre Rancourt, CEO of Tetra Bio-Pharma Inc. “By exercising their warrants ahead of schedule, this further confirms Aphira’s commitment to accelerate Tetra’s development work. I am pleased to report to shareholders that Tetra is in a solid financial position with over $4 million to continue advancing its strategic plan of becoming a leading bio-pharma organization focused on cannabis.”

About Aphria:

Aphria Inc., one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada. Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. We are committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders. We are the first public licensed producer to report positive cash flow from operations and the first to report positive earnings in consecutive quarters. For more information, visit www.Aphria.com.

About Tetra Bio-Pharma:

Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-Looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Guy Chamberland
Chief Science Officer
(514) 220-9225

Tetra Bio-Pharma Inc.
André Rancourt
Chief Executive Officer
(613) 689-0714
www.tetrabiopharma.com

Tags: , ,
Posted in Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Aphria Exercises Warrants for Gross Proceeds of $1.3 Million to Further Fund Tetra’s Clinical Trials $TBP.ca

Tetra Bio-Pharma Enters into Binding Term Sheet for Two Products with Panag Pharma $TBP.ca

Posted by AGORACOM-JC at 10:25 AM on Tuesday, March 14th, 2017

Tbp large

  • Entered into a binding term sheet with Panag Pharma Inc. for the development and commercialization of novel cannabinoid based formulations for the treatment of pain and inflammation
  • Combined total market potential of both products in the USA in 2014 is estimated over US$5.5 billion

OTTAWA, ONTARIO–(March 14, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF), announced today it has entered into a binding term sheet with Panag Pharma Inc. for the development and commercialization of novel cannabinoid based formulations for the treatment of pain and inflammation. Combined total market potential of both products in the USA in 2014 is estimated over US$5.5 billion.

Per the binding term sheet, Tetra will have exclusive access to sell the ocular and topical drug products in North America with right of first negotiation for outside U.S. and Canadian territories. In addition, Tetra will have a right of first negotiation for future products.

Tetra will be working in close collaboration with Panag’s team of experts to ensure a rapid and successful development. Tetra shall be responsible for 100% of the research and development of the Licensed Products. Tetra will own and control all regulatory approvals in the Territory, including the application and any other marketing authorizations within the Territory and shall be responsible for all aspects of commercializing the drug products.

Panag has developed potential new cannabinoid-based therapies for ocular and topical anti-inflammatory and pain markets. The total ocular anti-inflammatory market was estimated at over $3 billion in the USA in 2014 and includes conditions such as post-op inflammation, allergic conjunctivitis and inflammatory dry eye. Panag also developed a cannabinoid topical drug product for the treatment of local neuropathic and non-neuropathic pain. In 2014, the over the counter sales of topical analgesics were estimated at over $2.5 billion according to IMS.

“This announcement further demonstrates Tetra’s commitment to shareholders to add future products to our product portfolio in an effort of building a leading bio- pharmaceutical organization,” said Andre Rancourt, CEO of Tetra Bio-Pharma. “This will further allow Tetra to generate revenues in 2017 through its partnership with Panag. Tetra is going to work closely with Panag to exploit its innovative technology that indirectly acts on the CB2 receptor with the goal of launching several products in the retail market. This is in-line with Tetra’s goal of commercializing products pending legalization.”

According to Guy Chamberland, Chief Scientific Officer of Tetra Bio-Pharma, “We are going to prioritize the development of the ocular therapy as this is a promising innovative product and the potential financial reward will be significant. Tetra had already positioned itself to become a leader in topical pain relief with its PPTGR technology. With the Panag partnership, Tetra is going to modify its development plans to accelerate bringing an innovative cannabinoid topical drug product to the market. The Panag team is going to strengthen Tetra’s overall scientific knowledge and expertise base making it one of the leading biotechnology companies developing cannabinoid-based therapies.”

About Panag Pharma:

Panag Pharma Inc. is a Canadian based bio-tech company focused on the development of novel cannabinoid based formulations for the treatment of pain and inflammation. Panag believes that pain relief should be safe, non-addictive and above all; effective. The Panag Pharma team of PhD scientists and medical doctors are among the world’s leading researchers and clinicians in the area of pain treatment and management. They bring a combined experience of over 100 years in research and clinical care of people dealing with chronic pain and inflammatory conditions. Panag’s current pipeline of pain relief products include formulations for the topical application to the skin, the eye and other mucous membranes. Recently approved by Health Canada and currently undergoing clinical trials, Panag Pharma’s Topical AOTC provides a new approach to the treatment of chronic pain and inflammation.

About Tetra Bio-Pharma:

Tetra Bio Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Guy Chamberland
Chief Science Officer
(514) 220-9225

Tetra Bio-Pharma Inc.
Andre Rancourt
Chief Executive Officer
(343) 689-0714
www.tetrabiopharma.com

Tags: ,
Posted in Featured, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma Enters into Binding Term Sheet for Two Products with Panag Pharma $TBP.ca

« Older Entries
Newer Entries »